Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Ga-Young | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Kim, Dajung | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Lee, Won-Sik | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Jung, Sung-Hoon | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.date.accessioned | 2023-12-15T15:10:09Z | - |
dc.date.available | 2023-12-15T15:10:09Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89589 | - |
dc.description.abstract | IntroductionPegylated granulocyte colony-stimulating factor (G-CSF) has been widely used for preventing febrile neutropenia in various types of cancer treatment. In the present study, we prospectively evaluated the safety and efficacy of pegfilgrastim as a primary prophylaxis of febrile neutropenia and infection among patients with relapsed refractory multiple myeloma (RRMM) treated with pomalidomide-based regimens.MethodsThirty-three patients with RRMM who received pomalidomide and dexamethasone (Pd) with or without cyclophosphamide (PCd) were enrolled in this study. Twenty-eight patients were treated with PCd and 5 patients were treated with Pd. All patients were given pegfilgrastim subcutaneously with a single administration performed on the first day of each cycle as primary prophylaxis until the fourth cycle.ResultsThe median age of the patients was 75 (range 56-85), and the median prior line of therapy was 2 (range 2-6). Seventeen patients (51.5%) had any grade of neutropenia and 20 (60.6%) had any grade of thrombocytopenia before starting pomalidomide treatment. During the 4 cycles of treatment, grade 3 or more neutropenia occurred in 17 patients (51.5%), and 4 (12.1%) experienced grade 3 or more febrile neutropenia. Grade 3 or more infections occurred in 5 patients (15.2%). Interestingly, the patients with markedly increased ANC of more than 2 x 109/L compared to baseline ANC after 7 days of pegfilgrastim at 1st cycle of treatment showed a significantly lower incidence of grade 3-4 neutropenia. The most common adverse event of pegfilgrastim was fatigue, and all the adverse events caused by pegfilgrastim were grade 1 or 2. And there was no significant change in the immune cell population and cytokines during the administration of pegfilgrastim.DiscussionConsidering that this study included elderly patients with baseline neutropenia, pegylated G-CSF could be helpful to prevent severe neutropenia, febrile neutropenia, or infection in patients with RRMM. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170) | - |
dc.type | Article | - |
dc.identifier.wosid | 001097619200001 | - |
dc.identifier.doi | 10.3389/fonc.2023.1209110 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, v.13 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85176284733 | - |
dc.citation.title | FRONTIERS IN ONCOLOGY | - |
dc.citation.volume | 13 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | pegfilgrastim | - |
dc.subject.keywordAuthor | prophylaxis | - |
dc.subject.keywordAuthor | febrile neutropenia | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordAuthor | pomalidomide | - |
dc.subject.keywordPlus | DAILY FILGRASTIM | - |
dc.subject.keywordPlus | FEBRILE NEUTROPENIA | - |
dc.subject.keywordPlus | G-CSF | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | PEGFILGRASTIM | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | CYCLE | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.